The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia.

Vaccination of 'mid-adults,' including those at higher risk, results in higher number needed to vaccinate than that seen for younger people ...

AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...

There was an increase in quarterly prescription rates from 4.2% in July to September 2021 to 23.5% in July to September 2023. (HealthDay News) — From 2021 to 2023, there was an increase in ...

According to Soleno Therapeutics, the FDA required more time to review responses to recent information requests.

STS101 is an investigational DHE nasal powder product administered through a proprietary nasal delivery device.